CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-03-25): Early liver biopsy important in alcoholic cirrhosis

Drug & Device Development

Early liver biopsy important in alcoholic cirrhosis

Last Updated: 2011-03-25 13:53:21 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Early liver biopsy is indicated in patients who require hospital admission with acute deterioration of alcoholic cirrhosis, UK and Austrian researchers report in a March 2nd online paper in the Journal of Hepatology.

As Dr. Rajeshwar P. Mookerjee told Reuters Health by email, "Patients with alcoholic hepatitis have a high acute mortality and thus there is a need to accurately diagnose this clinical state."

"Early liver biopsy in patients presenting with acute deterioration of alcoholic cirrhosis is safe in units with the facilities to provide this service," he added, and it provides important confirmatory diagnostic and prognostic information.

Dr. Mookerjee of Royal Free Hospital, London, and colleagues examined the success of the approach in helping to diagnose and grade acute alcoholic steatohepatitis (ASH).

Sixty-eight patients with acute deterioration of alcoholic cirrhosis underwent a liver biopsy within 7 days of admission. The biopsies were processed using routine stains and K8/18 immunohistochemistry to characterize hepatocellular ballooning.

The team found that the presence of a systemic inflammatory response (SIRS) suggestive of ASH in 36 patients, predicted severe ASH histologically in only 50%. Moreover, in 41% of SIRS negative patients, thought not to have ASH, a diagnosis of ASH was subsequently confirmed on histological grading.

During follow-up of 28 days, 19 patients died. Most of the deaths were associated with sepsis and progressive organ failure.

Patients who had ASH on biopsy and were SIRS positive had a significantly greater risk of mortality compared to those that were SIRS positive but ASH negative. This was also true of those who were SIRS negative.

"Defining accurately the at-risk population from the larger group presenting with alcoholic cirrhosis helps target therapy to those likely to gain the most benefit (i.e. having the highest mortality without specific treatment) using interventions that carry increased risk of infection (e.g. corticosteroids)," continued Dr. Mookerjee.

"Those with cirrhosis but no liver inflammation (i.e. not alcoholic hepatitis) may benefit more from strategies such as treatment of latent infection with antibiotics," he concluded.

SOURCE: http://bit.ly/fZ3t6H

J Hepatol 2011.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.